SCHEMBL6421682

SCHEMBL6421682

O=Cc1c(Cl)ccn1S(=O)(=O)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 14/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
ALDH1A1 P00352 1/20 0.47
LMNA P02545 1/20 0.47
HPGD P15428 1/20 0.47
TSHR P16473 1/20 0.47
HTT P42858 1/20 0.47
MET P08581 1/20 0.42
CYP2C19 P33261 1/20 0.42
BCHE P06276 1/20 0.39
PPME1 Q9Y570 1/20 0.39
POLB P06746 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
HTR1A P08908 1/20 0.38
HTR1D P28221 1/20 0.38
HTR1B P28222 1/20 0.38
HTR1F P30939 1/20 0.38
HTR7 P34969 1/20 0.38
DRD3 P35462 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29778754 0.74 HTR6 (0.49) HTR6MEN1KMT2AALDH1A1LMNA
SCHEMBL23641456 0.74 HTR6 (0.49) HTR6MEN1KMT2AALDH1A1LMNA
SCHEMBL28901979 0.72 HTR6 (0.46) HTR6MEN1KMT2AALDH1A1LMNA
SCHEMBL1156250 0.71 KDM4E (0.50) HTR6MEN1KMT2AALDH1A1LMNA
SCHEMBL28282196 0.71 HTR6 (0.45) HTR6MEN1KMT2AALDH1A1LMNA
SCHEMBL1616366 0.70 PPME1 (0.60) HTR6MEN1KMT2AALDH1A1LMNA
SCHEMBL29778763 0.70 HTR6 (0.48) HTR6MEN1KMT2AALDH1A1LMNA
SCHEMBL18555846 0.70 HTR6 (0.44) HTR6MEN1KMT2AALDH1A1LMNA
SCHEMBL28189646 0.69 HTR6 (0.50) HTR6MEN1KMT2AALDH1A1LMNA
SCHEMBL31601808 0.69 HTR6 (0.63) HTR6MEN1KMT2AALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050227978-A1 Fibrosis inhibitor SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 2005-10-13 US disclosed
EP-1479384-A1 FIBROSIS INHIBITOR SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2004-11-24 EP disclosed
US-20040209939-A1 Pyrrole derivatives SUMITOMO PHARMACEUTICALS CO., LTD. 2004-10-21 US disclosed
US-6759429-B2 HAVING TRANSFORMING GROWTH FACTOR- BETA INHIBITORY ACTIVITY AND BEING USEFUL AS FIBROSIS INHIBITORS FOR ORGANS OR TISSUES SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 2004-07-06 US disclosed
CN-1466572-A Pyrrole derivatives ס����ҩ��ʽ���� 2004-01-07 CN disclosed
US-20030181496-A1 Pyrrole derivatives DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2003-09-25 US disclosed
EP-1310485-A1 PYRROLE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2003-05-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050227978-A1 Fibrosis inhibitor SMAD3, MMP1, SMAD2 HTR6 3939/4885MEN1 3581/4885KMT2A 3446/4885
US-20030181496-A1 Pyrrole derivatives NCOA1, PKD1, NR3C2 HTR6 3897/4885MEN1 2979/4885KMT2A 2631/4885
US-20040209939-A1 Pyrrole derivatives NCOA1, PKD1, NCOR1 HTR6 3924/4885MEN1 3109/4885KMT2A 2623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.